This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Galectin Drug is a Fatty Liver Flop

07/29/14 - 10:26 AM EDT

Across just about every biomarker for efficacy Galectin thought to measure, GR-MD-02 showed no difference from placebo in a phase I study.

READ FULL POST

Galectin Pays Stock Promoters to Entice Retail Investors

07/28/14 - 12:34 PM EDT

Like Galena BioPharma and The DreamTeam Group, Galectin is also paying for a promotional campaign designed to entice retail investors into buying its stock.

READ FULL POST

Access to Horizon Pharma Drugs Cut By Two Leading PBMs

07/28/14 - 10:56 AM EDT

Express Scripts and CVS Caremark are the largest and second-largest pharmacy benefits managers in the U.S. Both have been aggressive with efforts to rein in ever-escalating drug prices.

READ FULL POST

FDA Rejects AcelRx Painkiller Dispensing Device (Update)

07/28/14 - 09:44 AM EDT

AcelRx believes it can gather all the requested information and re-submit Zalviso to the FDA before the end of the year.

READ FULL POST

MannKind Afrezza Partnership News Coming Within Weeks

07/25/14 - 11:30 AM EDT

MannKind must report second-quarter financials before the end of the second week in August, which sets a quasi-deadline for Afrezza partner plans.

READ FULL POST

The Story Behind Sarepta's Firing of its Top Scientist

07/24/14 - 09:21 AM EDT

Sarepta terminates Chief Scientific Officer Art Krieg. Here's what I've learned about why he was fired.

READ FULL POST

Gilead Sovaldi $3.5 Billion: The Most Important Number in Biotech Earnings Season

07/23/14 - 05:44 PM EDT

In its first two quarters on the market, Sovaldi, a pill used to treat hepatitis C, has delivered $5.8 billion in revenue to Gilead. Remarkable.

READ FULL POST

Puma Shares Soar When Wall Street Misplays Expectation Game

07/23/14 - 12:26 PM EDT

Puma is why so many investors love to speculate on biotech stocks. A contrarian trade against a heavily expected outcome can return a fortune.

READ FULL POST

Inovio Declares Spin-Laden Victory With DNA Vaccine

07/23/14 - 10:17 AM EDT

Inovio's analysis of the VGX-3100 study omits an unknown number of patients, calling the results into question.

READ FULL POST

Gilead Expected to Post Sky-High Hep C Sales in June Quarter

07/22/14 - 12:12 PM EDT

The buyside "whisper number" for Sovaldi sales is $3.5 billion. But everyone who follows Gilead knows this, which means the "whispered" whisper number for sales is $4 billion or more.

READ FULL POST

Adam Feuerstein is a senior columnist at TheStreet in charge of covering biotechnology and pharmaceutical stocks.

Feuerstein has been a financial journalist for more than 20 years. He joined TheStreet in 2001, leaving in 2005 for a two-year stint as a biotech analyst for a New York-based investment management firm. Feuerstein rejoined TheStreet in 2007. Prior to his work at TheStreet, Feuerstein wrote about Internet startups and business software for Upside.com. Covering the dot-com boom and bust of the 1990s and early 2000s made Feuerstein very cynical, a trait he applies to great effect by highlighting the often-overlooked risks of biotech stock investing. In what can only be considered a high compliment, a particularly promotional sell-side analyst once warned his clients that Feuerstein "attacks viciously".

Expand Bio +

Feuerstein lives near Boston with his wife, two kids and a yellow lab-golden retriever named Max. When Feuerstein is not writing article and blog posts for TheStreet, he's tweeting. In fact, when Feuerstein is working, he's tweeting. All the time. He also runs, bikes, watches a lot of English soccer matches (Go Spurs!) and loves to cook.

Close Bio -

Markets

DOW 16,880.36 -31.75 -0.19%
S&P 500 1,970.07 +0.12 0.01%
NASDAQ 4,462.9020 +20.2040 0.45%

Adam's Tweets

Brokerage Partners

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs